Business Context and Reporting Period
Company: Helix Acquisition Corp. II (Note: The input metadata references "Bridgebio Oncology," but the filing text is for Helix Acquisition Corp. II, a Cayman Islands special purpose acquisition company).
Reporting Period: Quarter ended September 30, 2024.
Business Overview: The Company is a blank check company formed to effect a merger, share exchange, or asset acquisition with one or more businesses, focusing on healthcare and healthcare-related industries. As of September 30, 2024, the Company had not commenced any operations. All activity relates to formation, the Initial Public Offering (IPO) consummated on February 13, 2024, and identifying a target for a Business Combination.
Key Financial Metrics
| Metric | Value (Q3 2024) | Value (YTD 9 Months 2024) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Income | $2,333,358 | $5,646,336 |
| Operating Expenses | $146,852 (G&A) + $77,400 (Share-based comp) | $365,896 (G&A) + $194,172 (Share-based comp) |
| Interest Income (Trust Account) | $2,554,610 | $6,203,404 |
| Cash and Cash Equivalents | $1,785,636 | $1,785,636 |
| Marketable Securities (Trust Account) | $190,203,404 | $190,203,404 |
| Total Assets | $192,332,795 | $192,332,795 |
| Total Liabilities | $5,646,690 | $5,646,690 |
| Deferred Underwriting Fee | $5,520,000 | $5,520,000 |
| Class A Shares Subject to Redemption | 18,400,000 shares ($190,203,404) | 18,400,000 shares ($190,203,404) |
Material Changes vs. Prior Period
- Operational Status: The Company transitioned from a pre-IPO shell company to a post-IPO SPAC. In the prior comparable periods (Q3 and YTD 2023), the Company had no operations, no revenue, and no net income. In 2024, the Company generated significant net income solely from interest earned on the Trust Account.
- Capital Structure: Following the February 2024 IPO, the Company raised $184,000,000 in gross proceeds from Public Shares and $5,090,000 from Private Placement Shares. $184,000,000 was deposited into the Trust Account.
- Balance Sheet: Total assets increased from $332,894 at December 31, 2023, to $192,332,795 at September 30, 2024, driven by the Trust Account balance.
- Share Capitalization: The Company effected share capitalizations in February 2024, resulting in 4,600,000 Class B ordinary shares outstanding.
Outlook, Risks, and Management Commentary
- Business Combination Deadline: The Company has 24 months from the closing of the IPO (February 13, 2024) to complete an initial Business Combination. If not completed, the Company will liquidate and redeem Public Shares.
- Liquidity: The Company holds $1,785,636 in cash outside the Trust Account to fund operations, including due diligence and administrative costs. Management believes this is sufficient for the 24-month period but may require additional financing or Working Capital Loans from the Sponsor if costs exceed estimates.
- Redemption Rights: Public shareholders have the right to redeem their shares for a pro-rata portion of the Trust Account upon the completion of a Business Combination or liquidation. The redemption value is approximately $10.34 per share as of September 30, 2024.
- Risks: The Company is an emerging growth company with no operating history. Risks include the inability to complete a Business Combination, potential dilution from share issuances, and the possibility that the Trust Account value may be reduced by taxes or claims.
- Deferred Fees: A deferred underwriting fee of $5,520,000 is payable only upon the successful completion of a Business Combination.
Investor Verification Checklist
- Trust Account Yield: Verify the current interest rate environment and its impact on the Trust Account balance, which currently stands at $190.2 million (including ~$6.2 million in interest).
- Redemption Value: Confirm the per-share redemption value ($10.34) and the potential for fluctuations based on interest income and tax liabilities.
- Extension Options: Review the Company's charter for any provisions allowing extensions of the 24-month completion window and the associated costs or shareholder vote requirements.
- Working Capital Sufficiency: Assess whether the $1.8 million in cash outside the Trust Account is adequate to cover operating expenses until the deadline or a Business Combination is announced.
- Deferred Underwriting Fee: Note the $5.52 million liability that will reduce net proceeds to the Company upon a successful merger.